GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Launxp Biomedical Co Ltd (ROCO:6876) » Definitions » EBIT

Launxp Biomedical Co (ROCO:6876) EBIT : NT$-89.85 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Launxp Biomedical Co EBIT?

Launxp Biomedical Co's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was NT$-37.83 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-89.85 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Launxp Biomedical Co's annualized ROC % for the quarter that ended in Jun. 2024 was -355.80%. Launxp Biomedical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -1,912.16%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Launxp Biomedical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -21.39%.

Launxp Biomedical Co EBIT Historical Data

The historical data trend for Launxp Biomedical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Launxp Biomedical Co EBIT Chart

Launxp Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBIT
-28.67 -34.69 -43.42 -80.78

Launxp Biomedical Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial -17.52 -25.90 -28.77 -52.02 -37.83

Competitive Comparison of Launxp Biomedical Co's EBIT

For the Biotechnology subindustry, Launxp Biomedical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Launxp Biomedical Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Launxp Biomedical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Launxp Biomedical Co's EV-to-EBIT falls into.


Launxp Biomedical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-89.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Launxp Biomedical Co  (ROCO:6876) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Launxp Biomedical Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-76.45 * ( 1 - -0.33% )/( (22.46 + 20.655)/ 2 )
=-76.702285/21.5575
=-355.80 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=206.489 - 20.011 - ( 179.734 - max(0, 21.492 - 185.51+179.734))
=22.46

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=161.885 - 11.348 - ( 133.716 - max(0, 12.771 - 142.653+133.716))
=20.655

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Launxp Biomedical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-75.664/( ( (4.398 + max(-14.849, 0)) + (3.516 + max(-2.887, 0)) )/ 2 )
=-75.664/( ( 4.398 + 3.516 )/ 2 )
=-75.664/3.957
=-1,912.16 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.009 + 0 + 5.687) - (20.011 + 0 + 0.534)
=-14.849

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.334 + 0 + 7.603) - (11.348 + 0 + 0.476)
=-2.887

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Launxp Biomedical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-89.848/419.950
=-21.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Launxp Biomedical Co EBIT Related Terms

Thank you for viewing the detailed overview of Launxp Biomedical Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Launxp Biomedical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Launxp Biomedical Co Ltd (ROCO:6876) » Definitions » EBIT
Comparable Companies
ROCO:4170 ROCO:7607 ROCO:6999 ROCO:6549 ROCO:6917 ROCO:4197 ROCO:6744 ROCO:6662 ROCO:6827 ROCO:6848 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
10F, No. 51, Section 2, Gongyi Road, Nantun District, Taichung, TWN, 408
Website
https://www.launxp.com
Launxp Biomedical Co Ltd is a company that researches, designs and develops Cancer drug rapid screening platform and Early development evaluation and technology licensing of generic drugs for cancer treatment. The company mainly focuses on the screening of development drugs, formulation of development strategies, project management, planning and execution of regulations and clinical trials, etc.

Launxp Biomedical Co Headlines

No Headlines